| phosphodiesterase 4C, cAMP-specific |
GW-1929 |
Phosphodiesterase PDE4 |
88% |
7.45uM |
NoneNone |
View
|
| phosphodiesterase 4D |
GW-1929 |
Phosphodiesterase PDE4 |
88% |
7.45uM |
NoneNone |
View
|
| phosphodiesterase 4B, cAMP specific |
GW-1929 |
Phosphodiesterase PDE4 |
88% |
7.45uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
CYPROHEPTADINE |
Calcium Channel Type L, Phenylalkylamine |
88% |
.438uM |
.426uM |
View
|
| Protein-tyrosine kinase, Fyn |
PERHEXILINE |
Protein Tyrosine Kinase, Fyn |
88% |
4.064uM |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
HEXACHLOROPHENE |
Adrenergic alpha2A |
88% |
5.4965uM |
2.0612uM |
View
|
| epidermal growth factor receptor |
MONTELUKAST |
Protein Tyrosine Kinase, EGF Receptor |
88% |
3.197uM |
NoneNone |
View
|
| cholinergic receptor, muscarinic 1 |
FLUNARIZINE |
Muscarinic M1 |
88% |
2.936uM |
.707uM |
View
|
| adrenergic receptor, alpha 2a |
EPINEPHRINE |
Imidazoline I2, Central |
88% |
.232uM |
.154uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
EPINEPHRINE |
Imidazoline I2, Central |
88% |
.232uM |
.154uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
CYCLIZINE |
Dopamine Transporter |
88% |
.763uM |
.606uM |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
MOSAPRIDE |
CYP450-3A4 Inhibition |
88% |
.7uM |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
RAPAMYCIN |
CYP450-3A4 Inhibition |
88% |
2uM |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
RESVERATROL |
CYP450-3A4 Inhibition |
88% |
.6uM |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
PHENYLHYDRAZINE |
CYP450-2D6 Inhibition |
88% |
3uM |
NoneNone |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
IDEBENONE |
CYP450-2C9 Inhibition |
88% |
5uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
IDEBENONE |
CYP450-2C9 Inhibition |
88% |
5uM |
NoneNone |
View
|
| opioid receptor, sigma 1 |
BUFLOMEDIL |
Sigma1 |
88% |
2.1705uM |
.9122uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
BITHIONOL |
CYP450-2C9 Inhibition |
88% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
BITHIONOL |
CYP450-2C9 Inhibition |
88% |
NoneNone |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 2 |
TENIDAP |
Cyclooxygenase COX-2 |
88% |
.267uM |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
TENIDAP |
Cyclooxygenase COX-2 |
88% |
.267uM |
NoneNone |
View
|
| epidermal growth factor receptor |
METHYLDOPA |
Protein Tyrosine Kinase, EGF Receptor |
88% |
5.228uM |
NoneNone |
View
|
| melanocortin 4 receptor |
GRAMICIDIN |
Melanocortin MC4 |
88% |
3.313uM |
3.186uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type IV, alpha |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type III, alpha |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type II, beta |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type I, beta |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
PROMETHAZINE |
Sodium Channel, Site 2 |
86% |
2.37uM |
2.162uM |
View
|
| A3 adenosine receptor |
RABEPRAZOLE |
Adenosine A3 |
86% |
3.219uM |
1.82uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
PROMETHAZINE |
Calcium Channel Type L, Benzothiazepine |
86% |
2.779uM |
2.47uM |
View
|
| adrenergic receptor, alpha 2b |
RABEPRAZOLE |
Adrenergic alpha2B |
86% |
1.737uM |
.793uM |
View
|
| adrenergic receptor, alpha 1b |
RALOXIFENE |
Adrenergic alpha1B |
86% |
2.693uM |
1.491uM |
View
|
| adrenergic receptor, alpha 2a |
BENZETHONIUM CHLORIDE |
Adrenergic alpha2A |
86% |
3.102uM |
1.163uM |
View
|
| thromboxane A synthase 1 |
SB-203580 |
Thromboxane Synthetase |
86% |
.494uM |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
SB-203580 |
Thromboxane Synthetase |
86% |
.494uM |
NoneNone |
View
|
| dopamine receptor 2 |
ASTEMIZOLE |
Dopamine D2L |
86% |
4.521uM |
1.507uM |
View
|
| caspase 1 |
TRIAMTERENE |
Protease, Caspase 1 |
86% |
3.663uM |
NoneNone |
View
|
| caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) |
TRIAMTERENE |
Protease, Caspase 1 |
86% |
3.663uM |
NoneNone |
View
|
| caspase 3, apoptosis related cysteine protease |
TRIAMTERENE |
Protease, Caspase 1 |
86% |
3.663uM |
NoneNone |
View
|
| caspase 2 |
TRIAMTERENE |
Protease, Caspase 1 |
86% |
3.663uM |
NoneNone |
View
|
| caspase 7 |
TRIAMTERENE |
Protease, Caspase 1 |
86% |
3.663uM |
NoneNone |
View
|
| caspase 6 |
TRIAMTERENE |
Protease, Caspase 1 |
86% |
3.663uM |
NoneNone |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
TRAZODONE |
Adrenergic alpha1D |
86% |
.265uM |
.13uM |
View
|
| adrenergic receptor, alpha 1b |
GENTIAN VIOLET |
Adrenergic alpha1B |
86% |
3.595uM |
1.99uM |
View
|
| A3 adenosine receptor |
GENTIAN VIOLET |
Adenosine A3 |
86% |
4.166uM |
2.355uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
ISOTRETINOIN |
Serotonin 5-HT2B |
86% |
.848uM |
.54uM |
View
|
| adrenergic receptor, alpha 2a |
METHYSERGIDE |
Adrenergic alpha2A |
86% |
1.631uM |
.611uM |
View
|
| 5-hydroxytryptamine receptor 6 |
MEPAZINE |
Serotonin 5-HT6 |
86% |
1.837uM |
.853uM |
View
|
| opioid receptor, sigma 1 |
LOPERAMIDE |
Sigma1 |
86% |
.628uM |
.264uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
| mitogen activated protein kinase 14 |
1-(2-CHLOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
Protein Serine/Threonine Kinase, p38alpha |
85% |
.833uM |
NoneNone |
View
|
| mitogen-activated protein kinase 14 |
1-(2-CHLOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
Protein Serine/Threonine Kinase, p38alpha |
85% |
.833uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
LEFLUNOMIDE |
Dopamine Transporter |
85% |
2.884uM |
2.291uM |
View
|
| cholinergic receptor, muscarinic 2 |
L-744832 |
Muscarinic M2 |
85% |
3.568uM |
1.268uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
QUINACRINE |
Adrenergic alpha1D |
85% |
2.065uM |
1.015uM |
View
|
| aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) |
ACECLOFENAC |
Aldose Reductase |
85% |
1.288uM |
NoneNone |
View
|
| aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) |
ACECLOFENAC |
Aldose Reductase |
85% |
1.288uM |
NoneNone |
View
|
| aldo-keto reductase family 1, member B4 (aldose reductase) |
ACECLOFENAC |
Aldose Reductase |
85% |
1.288uM |
NoneNone |
View
|
| aldo-keto reductase family 1, member B1 (aldose reductase) |
ACECLOFENAC |
Aldose Reductase |
85% |
1.288uM |
NoneNone |
View
|
| adenine nucleotide translocase (DBSS) (Non-specific probe) |
NIMODIPINE |
Adenosine Transporter |
85% |
1.266uM |
.433uM |
View
|
| solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 |
NIMODIPINE |
Adenosine Transporter |
85% |
1.266uM |
.433uM |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 |
NIMODIPINE |
Adenosine Transporter |
85% |
1.266uM |
.433uM |
View
|
| concentrative Na+ nucleoside cotransporter (DBSS) |
NIMODIPINE |
Adenosine Transporter |
85% |
1.266uM |
.433uM |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 |
NIMODIPINE |
Adenosine Transporter |
85% |
1.266uM |
.433uM |
View
|
| histamine receptor H 1 |
ORPHENADRINE |
Histamine H1, Central |
85% |
1.241uM |
.144uM |
View
|
| acetylcholinesterase (YT blood group) |
EBASTINE |
Acetylcholinesterase |
85% |
7.4799uM |
NoneNone |
View
|
| collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
EBASTINE |
Acetylcholinesterase |
85% |
7.4799uM |
NoneNone |
View
|
| acetylcholinesterase |
EBASTINE |
Acetylcholinesterase |
85% |
7.4799uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
DESLORATADINE |
Adrenergic, Norepinephrine Transporter |
85% |
1.116uM |
1.107uM |
View
|
| A3 adenosine receptor |
CLOMIPHENE |
Adenosine A3 |
85% |
5.35uM |
3.024uM |
View
|
| epidermal growth factor receptor |
ASTEMIZOLE |
Protein Tyrosine Kinase, EGF Receptor |
85% |
6.057uM |
NoneNone |
View
|
| Cytochrom P450-2C19 monooxygenase |
FINASTERIDE |
CYP450-2C19 Inhibition |
85% |
1uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
DIPHENHYDRAMINE |
Serotonin 5-HT2C |
85% |
.98uM |
.513uM |
View
|
| adenosine A2a receptor |
OXFENDAZOLE |
Adenosine A2A |
85% |
1.504uM |
.844uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
ECONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
89% |
3.014uM |
2.93uM |
View
|
| arachidonate 15-lipoxygenase |
KETOCONAZOLE |
Lipoxygenase 15-LO |
89% |
5.425uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase, second type |
KETOCONAZOLE |
Lipoxygenase 15-LO |
89% |
5.425uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
KETOCONAZOLE |
Lipoxygenase 15-LO |
89% |
5.425uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2A |
FENOFIBRATE |
Serotonin 5-HT2A |
89% |
2.118uM |
.605uM |
View
|
| opioid receptor, sigma 1 |
DEXCHLORPHENIRAMINE |
Sigma1 |
89% |
1.658uM |
.697uM |
View
|
| thromboxane A synthase 1 |
SULCONAZOLE |
Thromboxane Synthetase |
89% |
.183uM |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
SULCONAZOLE |
Thromboxane Synthetase |
89% |
.183uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
DANAZOL |
Dopamine Transporter |
89% |
6.842uM |
5.436uM |
View
|
| arachidonate 15-lipoxygenase, second type |
BETA-ESTRADIOL |
Lipoxygenase 15-LO |
89% |
11.295uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
BETA-ESTRADIOL |
Lipoxygenase 15-LO |
89% |
11.295uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
BETA-ESTRADIOL |
Lipoxygenase 15-LO |
89% |
11.295uM |
NoneNone |
View
|
| nuclear receptor subfamily 3, group C, member 1 |
ETHINYLESTRADIOL |
Glucocorticoid |
89% |
1.71uM |
.777uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
4-OCTYLPHENOL |
Dopamine Transporter |
89% |
8.491uM |
6.746uM |
View
|
| prostaglandin-endoperoxide synthase 2 |
PHENOTHIAZINE |
Cyclooxygenase COX-2 |
89% |
.532uM |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
PHENOTHIAZINE |
Cyclooxygenase COX-2 |
89% |
.532uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
TIRILAZAD |
Calcium Channel Type L, Benzothiazepine |
89% |
2.694uM |
2.395uM |
View
|
| potassium voltage-gated channel, subfamily H, member 8 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 6 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 7 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 2 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 5 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 3 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 4 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
| Cytochrom P450-1A2 monooxygenase |
BW-723C86 |
CYP450-1A2 Inhibition |
89% |
.8738uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
PERHEXILINE |
Calcium Channel Type L, Benzothiazepine |
89% |
1.0569uM |
.9394uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
PERHEXILINE |
Calcium Channel Type L, Benzothiazepine |
89% |
1.0569uM |
.9394uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
PERHEXILINE |
Calcium Channel Type L, Benzothiazepine |
89% |
1.0569uM |
.9394uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
PERHEXILINE |
Calcium Channel Type L, Benzothiazepine |
89% |
1.0569uM |
.9394uM |
View
|
| thromboxane A synthase 1 |
GRAMICIDIN |
Thromboxane Synthetase |
88% |
.774uM |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
GRAMICIDIN |
Thromboxane Synthetase |
88% |
.774uM |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
METHAPYRILENE |
Adrenergic alpha2A |
88% |
1.165uM |
.437uM |
View
|
| Sigma-2 Receptor |
BROMHEXINE |
Sigma2 |
88% |
.059uM |
.036uM |
View
|
| arachidonate 15-lipoxygenase, second type |
FERULIC ACID |
Lipoxygenase 15-LO |
88% |
3.975uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
FERULIC ACID |
Lipoxygenase 15-LO |
88% |
3.975uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
FERULIC ACID |
Lipoxygenase 15-LO |
88% |
3.975uM |
NoneNone |
View
|
| histamine receptor H 2 |
BENZTROPINE |
Histamine H2 |
88% |
1.206uM |
1.185uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, voltage-gated, type III, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, voltage-gated, type I, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, voltage-gated, type II, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|